Neurological conditions, including ALS, stroke recovery, spinal cord injury, Parkinson’s disease, and multiple sclerosis, represent one of the most active areas of mesenchymal stem cell research, driven by the lack of effective standard treatments for most of these conditions and the biological plausibility of MSC neuroprotective and anti-inflammatory mechanisms. The evidence base for adipose-derived stem cell neurological applications is earlier-stage than orthopedics or aesthetics. Most published data is from Phase 1 safety trials and early Phase 2 studies, with larger randomized trials currently recruiting. This post reviews the mechanism, the condition-by-condition evidence, the active trial pipeline, and the expanded access framework for patients who cannot wait for trial completion.
TLDR: ADSCs have neuroprotective and anti-inflammatory properties being investigated in ALS, stroke, spinal cord injury, Parkinson’s disease, and multiple sclerosis. The evidence base is earlier-stage than orthopedics. Most published data is Phase 1 safety and early Phase 2. Active trials are recruiting. No ADSC neurological therapy is FDA-approved. Expanded access through the Reagan-Udall Navigator is the most legitimate near-term pathway for patients with serious neurological conditions who cannot wait for trial completion.
Important Disclaimer: Save My Fat does not provide FDA-approved treatments or cures for any neurological condition, including ALS, Parkinson’s disease, multiple sclerosis, stroke, or spinal cord injury. No ADSC-based therapy for any neurological condition has received FDA approval as of the date of this post. The neurological stem cell space has been extensively exploited by unregulated clinics making false treatment claims, and the FDA has taken enforcement action against providers in that category. This post is based entirely on peer-reviewed published research and registered clinical trials. Banking adipose tissue does not guarantee eligibility, access, or clinical benefit from any future therapy or clinical trial. All content is for educational purposes only and does not constitute medical advice. Consult your neurologist or neurosurgeon before making any decisions about neurologic treatment or research participation.
Patients and caregivers dealing with ALS, Parkinson’s, stroke, or spinal cord injury are among the most motivated and thorough researchers in any patient population. When standard medicine has little to offer, people look further. The ADSC neurological research pipeline is real, active, and scientifically grounded. It is also earlier-stage than other ADSC application categories, and it exists alongside a well-documented landscape of unregulated clinics that have exploited neurological patients with false treatment claims. Knowing the difference between legitimate clinical research and predatory marketing is essential for anyone researching this space.
The FDA has issued multiple warning letters and taken enforcement action against clinics offering unproven stem cell treatments for neurological conditions including ALS and Parkinson’s disease. The legitimate research is happening in registered clinical trials with IRB oversight, published safety and efficacy data, and the full regulatory apparatus that patient protection requires. That research is the subject of this post.
The sections that follow cover the MSC neuroprotective mechanism, the condition-by-condition evidence for ALS, stroke, spinal cord injury, Parkinson’s disease, and multiple sclerosis, the active trial pipeline, the expanded access and trial enrollment options for patients evaluating near-term access, and a practical framework for distinguishing legitimate research from predatory clinics.
Why ADSCs Have Neurological Research Activity
The Neuroprotective Mechanism
Mesenchymal stem cells, including adipose-derived MSCs, exert neuroprotective effects through three overlapping mechanisms:
- Anti-inflammatory paracrine signaling, where MSC-secreted IDO, TGF-beta, and PGE2 reduce neuroinflammation, which is a key driver of neurodegeneration in ALS, Parkinson’s, and MS.
- Neurotrophic factor secretion, where ADSCs secrete BDNF (brain-derived neurotrophic factor), NGF (nerve growth factor), VEGF, and HGF, supporting neuron survival and axon regeneration.
- Immunomodulation, where in conditions with autoimmune components such as MS and some ALS subtypes, MSC regulatory T cell promotion and lymphocyte suppression reduce immune-mediated neuronal damage.
The 2019 MSC biology review from Pittenger and colleagues in npj Regenerative Medicine describes these mechanisms in physician-appropriate depth. The 2018 MSC clinical review from Galipeau and Sensebe in Cell Stem Cell covers the immunomodulatory mechanism in clinical contexts. Published research on MSC neurological applications has extended these mechanisms into Phase 1 and Phase 2 clinical investigation across multiple neurological indications. Save My Fat’s comparison of mesenchymal stem cells across sources puts the adipose source in context against the alternatives.
The Blood-Brain Barrier Challenge
The primary biological challenge for ADSC neurological applications is the blood-brain barrier, the selective permeability barrier that limits what can enter the central nervous system. Most published neurological MSC trials use intrathecal (spinal fluid) or intracerebral injection routes rather than intravenous delivery to address this challenge. The published literature on MSC delivery routes in CNS conditions and preclinical and early clinical research on Parkinson’s neuroprotection both cover the delivery-route considerations. Administration route is a key variable across neurological ADSC trials and affects both the evidence base and any future clinical protocol, because the cells that do not cross the BBB cannot act on CNS tissue directly.
Condition-by-Condition Evidence Review
ALS (Amyotrophic Lateral Sclerosis)
ALS is the condition with the most desperate unmet clinical need and therefore the most documented exploitation by unregulated stem cell clinics. It is also a condition with active, registered, IRB-approved MSC clinical trials. Published Phase 1 data from intrathecal MSC trials in ALS patients have reported safety and tolerability, with preliminary signals of slowed disease progression in some study arms. Larger Phase 2 trials are currently recruiting.
Honest context matters here more than anywhere else in the evidence base. ALS is a rapidly progressive disease with a poor prognosis. Phase 1 safety data is encouraging but does not establish efficacy, and preliminary progression signals from early-phase studies do not replicate consistently in every case. No MSC therapy has been approved for ALS. The distinction between a registered Phase 1 trial with IRB oversight and published safety data, and a clinic charging tens of thousands of dollars for unproven injections, is not subtle. It is the difference between science and exploitation, and it is the single most important distinction for any ALS patient or caregiver to understand before pursuing any stem cell option.
Stroke Recovery
Post-stroke neurological recovery is an active MSC research area. Published data from Phase 1 and Phase 2 trials of intravenous and intracerebral MSC administration in ischemic stroke patients have reported improvements in NIHSS scores, modified Rankin Scale outcomes, and reduced infarct volume in some studies. Active stroke trials continue to expand the evidence base. The therapeutic window for stroke recovery interventions is a key variable in this evidence base. Trials vary significantly in the timing of MSC administration post-stroke, from days to months, and the evidence is heterogeneous across timing protocols, which is why systematic reviews in this space typically stratify by administration timing rather than pooling all results together.
Spinal Cord Injury
Spinal cord injury has a published MSC trial history dating back over a decade. Phase 1 and Phase 2 studies have examined both autologous and allogeneic MSC administration via intrathecal and intravascular routes in patients with complete and incomplete spinal cord injury. Published data has reported safety across the studies and functional improvement signals in incomplete spinal cord injury patients specifically, which is the patient population where preserved neural connections provide the biological substrate for the regenerative and neuroprotective mechanisms to act on. Active spinal cord injury trials are recruiting across both autologous and allogeneic approaches.
Parkinson’s Disease
Parkinson’s disease MSC research is earlier-stage than ALS or stroke. Preclinical data demonstrates neuroprotective effects via BDNF and GDNF secretion, as the published Parkinson’s neuroprotection literature documents. Phase 1 human trials are underway, with safety and preliminary efficacy data expected from current recruiting studies. Parkinson’s is a chronic, progressive condition where the neuroprotective timing argument for banking, meaning preserving cells before disease progression, is particularly compelling from a biological standpoint. That is a separate argument from any claim about current access to treatment, which does not exist.
Multiple Sclerosis (Neurological Component)
Multiple sclerosis sits at the intersection of the autoimmune and neurological evidence arcs. The immunomodulatory mechanism drives the autoimmune component, and the neuroprotective mechanism addresses the neurodegeneration that accumulates across relapses. MSC trials in MS are the most advanced in the neurological category, with Phase 2 data showing relapse rate reductions and MRI lesion stabilization in some study arms. The 2018 MSC clinical review covers the evidence synthesis across both the autoimmune and neurological dimensions of the disease. Save My Fat’s overview of ADSC autoimmune and inflammatory research covers the autoimmune mechanism in more depth.
Active Clinical Trials
Active recruiting trials for MSC and ADSC neurological applications are listed on ClinicalTrials.gov across all conditions covered in this post. Separate searches capture each main indication area: general neurological ADSC trials, MSC trials in ALS, MSC trials in stroke, and MSC trials in spinal cord injury. Save My Fat’s guide on finding legitimate clinical trials covers the framework patients should use when evaluating specific listings, and the explainer on what ClinicalTrials.gov phases mean is useful context for interpreting the registry entries.
Expanded Access for Serious Neurological Conditions
For patients with ALS, advanced multiple sclerosis, spinal cord injury, or other serious neurological conditions who cannot wait for trial completion, expanded access is the most legitimate near-term pathway to investigational ADSC or MSC therapy. The Reagan-Udall Foundation’s Expanded Access Navigator guides both patients and physicians through the expanded access application process, and Save My Fat’s overview of expanded access programs covers the framework in patient-facing depth.
The key criteria are serious or life-threatening condition, no comparable alternative therapy, physician initiation of the request, and sponsor agreement to provide the investigational product. For ALS specifically, the life-threatening standard is unambiguously met. The challenge is identifying a sponsor with an active expanded access program for a qualifying MSC product, which is where the Navigator provides the most practical value by connecting patients and physicians directly with the sponsor identification step that typically stalls expanded access applications. The FDA’s approved cellular and gene therapy products database and Save My Fat’s overview of Right to Try and how it differs together cover the alternative regulatory pathway that some patients ask about separately.
Banking Implications for Neurological Patients
The Timing Argument Is Most Urgent Here
For patients with progressive neurological conditions, the case for banking as early as possible is stronger than in any other application category. ALS progresses rapidly. Parkinson’s progresses over years. Multiple sclerosis relapses create cumulative neurological damage. The biological stress of disease progression and the systemic inflammation of neurodegeneration affect ADSC quality over time, and the published MSC biology literature documents how age and disease state both reduce MSC function. The cells banked at diagnosis, or before symptoms begin in a patient with genetic risk factors, are the highest-quality cells that patient will ever have available. Save My Fat’s complete guide to banking covers the timing rationale in patient-facing depth.
Autologous Cells and Neurological Protocols
Many neurological MSC trials have used autologous cell protocols specifically to avoid immune rejection complications in patients whose neurological and immune systems may already be compromised. A patient who has banked autologous adipose-derived cells is better positioned for autologous neurological trial enrollment or expanded access than a patient who has not, because the protocols that require autologous starting material cannot be executed without autologous cells available. The MSC ALS clinical research literature illustrates how autologous protocols are structured, and Save My Fat’s overview of how banking works describes the banking process that preserves the autologous starting material.
What to Do If You Cannot Bank Now Due to Disease Progression
If a patient has advanced disease that makes the harvest procedure inadvisable, banking may not be feasible. The decision depends on the patient’s current overall health status and the clinical judgment of the treating physician, not on any universal rule. Patients in earlier stages who are otherwise healthy enough for a thirty-minute outpatient procedure under local anesthesia may still have the window open. Save My Fat’s overview of informed consent in regenerative medicine covers the consent framework, and a Save My Fat partner provider can evaluate specific cases in consultation with the treating neurologist.
How to Identify Legitimate Research from Predatory Clinics
This framework matters more in neurological conditions than in any other application category because the exploitation history is longer and more documented here. Four markers distinguish legitimate ADSC neurological research from predatory marketing.
First, the study is registered on ClinicalTrials.gov with an NCT number and a listed principal investigator. A study that cannot be found on the registry is not a legitimate clinical trial regardless of what its marketing materials claim.
Second, the study has IRB approval documented. Institutional Review Board oversight is a non-negotiable element of legitimate human subject research, and IRB approval documentation can be requested from the study investigators.
Third, the study publishes its safety and efficacy data in peer-reviewed journals. A study that has been running for years without publishing any data is either not actually a study or is producing results its sponsors do not want reviewed.
Fourth, the investigational product is provided at no charge to participants, or at documented manufacturing cost only. Legitimate clinical trials do not charge patients tens of thousands of dollars for the investigational product, because trial enrollment is research participation rather than treatment purchase.
Four red flags mark predatory stem cell clinics. Charging $10,000 to $100,000 for “stem cell treatments” for ALS, Parkinson’s, or spinal cord injury is the first. Claiming FDA approval or FDA clearance for cell therapies that are not on the FDA’s approved products list is the second. No published clinical trial data and no ClinicalTrials.gov registration is the third. Testimonials and before-and-after claims in place of clinical outcome data is the fourth. The regulatory framework at 21 CFR Part 1271 and Save My Fat’s overview of FDA regulations for adipose tissue together cover the compliance line that legitimate services operate within.
Evidence Summary Table
| Condition | Evidence Stage | Key Signal | Access Pathway |
|---|---|---|---|
| ALS | Phase 1 safety and early Phase 2 | Safety established, preliminary slowing signals | Clinical trial enrollment, expanded access |
| Stroke recovery | Phase 1 and 2 | NIHSS improvements, infarct reduction in some studies | Clinical trial enrollment |
| Spinal cord injury | Phase 1 and 2 | Safety across studies, functional improvement in incomplete SCI | Clinical trial enrollment, expanded access |
| Parkinson’s disease | Preclinical and Phase 1 | Neuroprotective signals preclinically, safety Phase 1 underway | Clinical trial enrollment |
| Multiple sclerosis | Phase 2 | Relapse reduction, MRI stabilization | Clinical trial enrollment, expanded access |
The MSC ALS clinical data, the stroke Phase 1 and 2 evidence, the spinal cord injury evidence base, the Parkinson’s neuroprotection research, and the MS clinical review literature together form the primary reference set for the evidence levels summarized in the table. None of the conditions listed has an FDA-approved ADSC-based therapy available, and all of the evidence should be understood as describing active research rather than current treatment.
Frequently Asked Questions
Are there legitimate clinical trials for ALS using stem cells?
Yes. Registered Phase 1 and Phase 2 trials investigating MSC-based approaches to ALS are listed through the MSC ALS trial search on ClinicalTrials.gov. These trials typically use intrathecal administration and autologous or allogeneic MSCs depending on the specific protocol. They are distinct from unregulated clinics offering unproven treatments, and the markers of legitimacy described earlier in this post are the way to distinguish them.
What is the difference between a registered ALS stem cell trial and a clinic offering stem cell injections for ALS?
A registered trial has IRB approval, published safety data, ClinicalTrials.gov registration, and no financial charge to participants for the investigational product. An unregulated clinic charging for ALS stem cell injections with no trial registration and no published data is operating outside the regulatory framework the FDA requires, and the FDA has issued warning letters to clinics in this category. The FDA approved products database lists every cellular therapy that has actually received approval, and any clinic claiming approval for a product not on that list is making a claim that can be independently verified as false.
Should a patient with early Parkinson’s bank their cells now?
Banking earlier in the disease course preserves higher-quality autologous cells, because MSC biological characteristics decline with age and with the systemic effects of progressive neurodegeneration. For a patient with early Parkinson’s who is otherwise healthy enough for a thirty-minute outpatient harvest under local anesthesia, the timing argument is strong. The decision should be made in consultation with the treating neurologist and a Save My Fat provider evaluating the patient’s specific situation, not on the basis of any general guidance including this post.
How does expanded access work for a patient with ALS who cannot enroll in a trial?
The treating physician submits an individual patient expanded access request to the FDA. The Reagan-Udall Navigator provides step-by-step guidance through the process and connects physicians with FDA staff who can answer specific questions. The sponsor of an active ALS MSC trial must independently agree to provide the investigational product, which is typically the most uncertain step in the process. Save My Fat’s expanded access overview covers the framework in more depth.
Key Takeaways
ADSCs have three neurological mechanisms under investigation: anti-inflammatory paracrine signaling, neurotrophic factor secretion including BDNF and NGF, and immunomodulation in conditions with autoimmune components. The three mechanisms overlap biologically, which is why the same cell type has research activity across conditions as different as ALS, stroke, and multiple sclerosis.
The blood-brain barrier limits intravenous delivery of MSCs to the central nervous system. Most neurological ADSC trials use intrathecal or intracerebral administration routes, and the administration route is a key variable that affects both the evidence base and any future clinical protocol.
Evidence stages by condition are uneven. ALS sits at Phase 1 and early Phase 2 with safety established and preliminary slowing signals. Stroke recovery is at Phase 1 and 2 with functional improvement signals in some protocols. Spinal cord injury is at Phase 1 and 2 with safety across studies and functional signals in incomplete injury patients. Parkinson’s is at Phase 1 with safety data expected from current trials. Multiple sclerosis is the most advanced in the neurological category at Phase 2, with relapse rate reductions and MRI stabilization reported.
No ADSC neurological therapy is FDA-approved. The research is legitimate and active. Unregulated clinics charging for unproven neurological stem cell treatments are a separate and exploitative category, and the FDA has issued warning letters and pursued enforcement action against clinics operating in that category.
The timing argument for banking is most urgent in progressive neurological conditions. Banking before disease progression reduces cell quality preserves the best available autologous starting material for whatever pathway eventually becomes available, and the window for banking depends on the patient’s overall health status rather than on any universal rule.
Expanded access through the Reagan-Udall Navigator is the most legitimate near-term pathway for patients with serious conditions who cannot wait for trial completion. It is not a guarantee of access, because FDA review and sponsor agreement are both required, but it is the appropriate regulatory mechanism for patients whose situations warrant investigational therapy outside of clinical trial enrollment.
Resources
Before taking any next step: adipose tissue banking is a preservation service for potential future use in FDA-regulated pathways, not a treatment or a guarantee of access to any specific clinical trial, therapy, or product. No ADSC-based therapy for any neurological condition is FDA-approved, and banking cannot be represented to patients as a treatment for any neurological disease. Consult your neurologist or neurosurgeon before making any decisions about neurologic treatment, trial enrollment, or banking. Physicians considering partnership should independently verify applicable state licensing and informed-consent requirements, particularly in Florida, Utah, and Nevada, which have stem cell-specific statutes.
For patients and caregivers, the Reagan-Udall Expanded Access Navigator is the recommended first resource for evaluating expanded access. Active neurological trial searches are available for general neurological ADSC trials and for ALS-specific trials. Save My Fat’s expanded access overview covers the regulatory framework in patient-facing terms, and the patient-facing introduction to adipose-derived stem cells covers the underlying biology.
For providers considering joining Save My Fat as a partner for adipose tissue banking, the Save My Fat provider program overview and the partner sign-up page are the starting resources.
Save My Fat provides adipose tissue banking services in partnership with L2 Bio for laboratory operations. Save My Fat does not provide medical treatments, clinical trial enrollment, or Expanded Access services.
This article is for educational purposes only and does not constitute medical or legal advice. Legal and medical review including neurology and neurosurgery input is required before publication. Please consult your neurologist or neurosurgeon before making any decisions about neurologic treatment or research participation.
